Similar articles

• Possible reasons for the inefficiency of Gram-negative bacterial vaccines.

  Wardlaw AC. Wardlaw AC. Prog Immunobiol Stand. 1971;5:508-12. Prog Immunobiol Stand. 1971. PMID: 4349834 No abstract available.
• Chemical and biological adjuvants capable of potentiating tumor cell vaccine.

  Chirigos MA, Stylos WA, Schultz RM, Fullen JR. Chirigos MA, et al. Cancer Res. 1978 Apr;38(4):1085-91. Cancer Res. 1978. PMID: 416906
• Enhanced resistance of Corynebacterium parvum-treated mice to infection by bacteria.

  Adlam C, Broughton ES, Scott MT. Adlam C, et al. J Med Microbiol. 1972 Feb;5(1):Pvii. J Med Microbiol. 1972. PMID: 4336739 No abstract available.
• Active immunotherapy of L1210 leukaemia applied after the graft of tumour cells.

  Mathé G, Pouillart P, Lapeyraque F. Mathé G, et al. Br J Cancer. 1969 Dec;23(4):814-24. doi: 10.1038/bjc.1969.101. Br J Cancer. 1969. PMID: 4312660 Free PMC article. No abstract available.
• The relationship between the protective and cross-reacting antigens of Brucella spp., Yersinia enterocolitica 0:9 and Salmonella serotypes of Kauffmann-White group N.

  Corbel MJ. Corbel MJ. Contrib Microbiol Immunol. 1979;5:50-63. Contrib Microbiol Immunol. 1979. PMID: 119612